Insights into the distinct roles of MMP-11 in tumor biology and future therapeutics (Review)
- Authors:
- Xu Zhang
- Shuai Huang
- Junchao Guo
- Li Zhou
- Lei You
- Taiping Zhang
- Yupei Zhao
-
Affiliations: Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100730, P.R. China - Published online on: February 18, 2016 https://doi.org/10.3892/ijo.2016.3400
- Pages: 1783-1793
This article is mentioned in:
Abstract
![]() |
![]() |
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI | |
Frisch SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 124:619–626. 1994. View Article : Google Scholar : PubMed/NCBI | |
Wei L and Shi YB: Matrix metalloproteinase stromelysin-3 in development and pathogenesis. Histol Histopathol. 20:177–185. 2005. | |
Wieczorek E, Jablonska E, Wasowicz W and Reszka E: Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review. Tumour Biol. 36:163–175. 2015. View Article : Google Scholar : | |
Geho DH, Bandle RW, Clair T and Liotta LA: Physiological mechanisms of tumor-cell invasion and migration. Physiology (Bethesda). 20:194–200. 2005. View Article : Google Scholar | |
Motrescu ER and Rio MC: Cancer cells, adipocytes and matrix metalloproteinase 11: A vicious tumor progression cycle. Biol Chem. 389:1037–1041. 2008. View Article : Google Scholar : PubMed/NCBI | |
Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, Duenas A, Taja L, Mendoza P, Garcia JA and Salcedo M: Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer. 5:682005. View Article : Google Scholar : PubMed/NCBI | |
Bartolomé RA, Ferreiro S, Miquilena-Colina ME, Martínez-Prats L, Soto-Montenegro ML, García-Bernal D, Vaquero JJ, Agami R, Delgado R, Desco M, et al: The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol. 174:602–612. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Chen Y, Huang L and Yu J: Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma. J Dermatol. 39:339–343. 2012. View Article : Google Scholar | |
Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI | |
Folgueras AR, Pendás AM, Sánchez LM and López-Otín C: Matrix metalloproteinases in cancer: From new functions to improved inhibition strategies. Int J Dev Biol. 48:411–424. 2004. View Article : Google Scholar : PubMed/NCBI | |
Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC and Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 348:699–704. 1990. View Article : Google Scholar : PubMed/NCBI | |
Pei D and Weiss SJ: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 375:244–247. 1995. View Article : Google Scholar : PubMed/NCBI | |
Deng H, Guo RF, Li WM, Zhao M and Lu YY: Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem Biophys Res Commun. 326:274–281. 2005. View Article : Google Scholar | |
Andarawewa KL, Motrescu ER, Chenard MP, Gansmuller A, Stoll I, Tomasetto C and Rio MC: Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res. 65:10862–10871. 2005. View Article : Google Scholar : PubMed/NCBI | |
Motrescu ER, Blaise S, Etique N, Messaddeq N, Chenard MP, Stoll I, Tomasetto C and Rio MC: Matrix metalloproteinase-11/ stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. Oncogene. 27:6347–6355. 2008. View Article : Google Scholar : PubMed/NCBI | |
Soni S, Mathur M, Shukla NK, Deo SV and Ralhan R: Stromelysin-3 expression is an early event in human oral tumorigenesis. Int J Cancer. 107:309–316. 2003. View Article : Google Scholar : PubMed/NCBI | |
Arora S, Kaur J, Sharma C, Mathur M, Bahadur S, Shukla NK, Deo SV and Ralhan R: Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis. Clin Cancer Res. 11:2272–2284. 2005. View Article : Google Scholar : PubMed/NCBI | |
Denys H, De Wever O, Nusgens B, Kong Y, Sciot R, Le AT, Van Dam K, Jadidizadeh A, Tejpar S, Mareel M, et al: Invasion and MMP expression profile in desmoid tumours. Br J Cancer. 90:1443–1449. 2004. View Article : Google Scholar : PubMed/NCBI | |
Kettunen E, Anttila S, Seppänen JK, Karjalainen A, Edgren H, Lindström I, Salovaara R, Nissén AM, Salo J, Mattson K, et al: Differentially expressed genes in nonsmall cell lung cancer: Expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet. 149:98–106. 2004. View Article : Google Scholar : PubMed/NCBI | |
Hourihan RN, O'Sullivan GC and Morgan JG: Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res. 23(1A): 161–165. 2003.PubMed/NCBI | |
von Marschall Z, Riecken EO and Rosewicz S: Stromelysin 3 is over expressed in human pancreatic carcinoma and regulated by retinoic acid in pancreatic carcinoma cell lines. Gut. 43:692–698. 1998. View Article : Google Scholar : PubMed/NCBI | |
Perret AG, Duthel R, Fotso MJ, Brunon J and Mosnier JF: Stromelysin-3 is expressed by aggressive meningiomas. Cancer. 94:765–772. 2002. View Article : Google Scholar : PubMed/NCBI | |
Mueller J, Brebeck B, Schmalfeldt B, Kuhn W, Graeff H and Höfler H: Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential. Virchows Arch. 437:618–624. 2000. View Article : Google Scholar | |
Wlodarczyk J, Stolte M and Mueller J: E-cadherin, beta-catenin and stromelysin-3 expression in de novo carcinoma of the colorectum. Pol J Pathol. 52:119–124. 2001. | |
Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P and Basset P: Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA. 90:1843–1847. 1993. View Article : Google Scholar : PubMed/NCBI | |
Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP and Rio MC: Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol. 15:535–541. 1997. View Article : Google Scholar : PubMed/NCBI | |
Laurell H, Bouisson M, Berthelemy P, Rochaix P, Dejean S, Besse P, Susini C, Pradayrol L, Vaysse N and Buscail L: Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J Gastroenterol. 12:3344–3351. 2006. View Article : Google Scholar : PubMed/NCBI | |
Barrasa JI, Olmo N, Santiago-Gómez A, Lecona E, Anglard P, Turnay J and Lizarbe MA: Histone deacetylase inhibitors upregulate MMP11 gene expression through Sp1/Smad complexes in human colon adenocarcinoma cells. Biochim Biophys Acta. 1823:570–581. 2012. View Article : Google Scholar : PubMed/NCBI | |
Genestie C, Zafrani B, Asselain B, Fourquet A, Rozan S, Validire P, Vincent-Salomon A and Sastre-Garau X: Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: Major importance of the mitotic count as a component of both grading systems. Anticancer Res. 18:571–576. 1998.PubMed/NCBI | |
Min KW, Kim DH, Do SI, Pyo JS, Kim K, Chae SW, Sohn JH, Oh YH, Kim HJ, Choi SH, et al: Diagnostic and prognostic relevance of MMP-11 expression in the stromal fibroblast-like cells adjacent to invasive ductal carcinoma of the breast. Ann Surg Oncol. 20(Suppl 3): S433–S442. 2013. View Article : Google Scholar | |
DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar | |
Fu J, Khaybullin R, Zhang Y, Xia A and Qi X: Gene expression profiling leads to discovery of correlation of matrix metalloproteinase 11 and heparanase 2 in breast cancer progression. BMC Cancer. 15:4732015. View Article : Google Scholar : PubMed/NCBI | |
Roscilli G, Cappelletti M, De Vitis C, Ciliberto G, Di Napoli A, Ruco L, Mancini R and Aurisicchio L: Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients. J Transl Med. 12:542014. View Article : Google Scholar : PubMed/NCBI | |
Lustosa SA, Saconato H, Atallah AN, Lopes Filho Gde J and Matos D: Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer. Meta-analysis of randomized clinical trials. Acta Cir Bras. 23:520–530. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zhao ZS, Chu YQ, Ye ZY, Wang YY and Tao HQ: Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol. 41:686–696. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yan D, Dai H and Liu JW: Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma. BMC Cancer. 11:1512011. View Article : Google Scholar : PubMed/NCBI | |
Asano T, Tada M, Cheng S, Takemoto N, Kuramae T, Abe M, Takahashi O, Miyamoto M, Hamada J, Moriuchi T, et al: Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res. 146:32–42. 2008. View Article : Google Scholar | |
Skoglund J, Emterling A, Arbman G, Anglard P and Sun XF: Clinicopathological significance of stromelysin-3 expression in colorectal cancer. Oncology. 67:67–72. 2004. View Article : Google Scholar : PubMed/NCBI | |
Bakkevold KE, Arnesjø B and Kambestad B: Carcinoma of the pancreas and papilla of Vater: Presenting symptoms, signs, and diagnosis related to stage and tumour site. A prospective multi-centre trial in 472 patients Norwegian Pancreatic Cancer Trial. Scand J Gastroenterol. 27:317–325. 1992. View Article : Google Scholar : PubMed/NCBI | |
Rouyer N, Wolf C, Chenard MP, Rio MC, Chambon P, Bellocq JP and Basset P: Stromelysin-3 gene expression in human cancer: An overview. Invasion Metastasis. 14:269–275. 1995. | |
Andarawewa KL, Boulay A, Masson R, Mathelin C, Stoll I, Tomasetto C, Chenard MP, Gintz M, Bellocq JP and Rio MC: Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res. 63:5844–5849. 2003.PubMed/NCBI | |
Noël A, Boulay A, Kebers F, Kannan R, Hajitou A, Calberg-Bacq CM, Basset P, Rio MC and Foidart JM: Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene. 19:1605–1612. 2000. View Article : Google Scholar : PubMed/NCBI | |
Masson R, Lefebvre O, Noël A, Fahime ME, Chenard MP, Wendling C, Kebers F, LeMeur M, Dierich A, Foidart JM, et al: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol. 140:1535–1541. 1998. View Article : Google Scholar : PubMed/NCBI | |
Kwon YJ, Hurst DR, Steg AD, Yuan K, Vaidya KS, Welch DR and Frost AR: Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines. Clin Exp Metastasis. 28:437–449. 2011. View Article : Google Scholar : PubMed/NCBI | |
Fromigue O, Louis K, Wu E, Belhacène N, Loubat A, Shipp M, Auberger P and Mari B: Active stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinase. Int J Cancer. 106:355–363. 2003. View Article : Google Scholar : PubMed/NCBI | |
Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP, Sautès-Fridman C, Basset P and Rio MC: High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res. 61:2189–2193. 2001.PubMed/NCBI | |
Krüger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V, Harbeck N, Gänsbacher B and Schmitt M: Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res. 61:1272–1275. 2001.PubMed/NCBI | |
Zucker S, Cao J and Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 19:6642–6650. 2000. View Article : Google Scholar | |
Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI | |
Overall CM and López-Otín C: Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer. 2:657–672. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kanharat N and Tuamsuk P: Correlation between microvascular density and matrix metalloproteinase 11 expression in prostate cancer tissues: A preliminary study in Thailand. Asian Pac J Cancer Prev. 16:6639–6643. 2015. View Article : Google Scholar : PubMed/NCBI | |
Rio MC: From a unique cell to metastasis is a long way to go: Clues to stromelysin-3 participation. Biochimie. 87:299–306. 2005. View Article : Google Scholar : PubMed/NCBI | |
Brasse D, Mathelin C, Leroux K, Chenard MP, Blaise S, Stoll I, Tomasetto C and Rio MC: Matrix metalloproteinase 11/ stromelysin-3 exerts both activator and repressor functions during the hematogenous metastatic process in mice. Int J Cancer. 127:1347–1355. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kasper G, Reule M, Tschirschmann M, Dankert N, Stout-Weider K, Lauster R, Schrock E, Mennerich D, Duda GN and Lehmann KE: Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: Involvement of the IGF-1 signalling pathway. BMC Cancer. 7:122007. View Article : Google Scholar : PubMed/NCBI | |
Jones L, Ghaneh P, Humphreys M and Neoptolemos JP: The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann NY Acad Sci. 880:288–307. 1999. View Article : Google Scholar : PubMed/NCBI | |
Johansson N, Ahonen M and Kähäri VM: Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci. 57:5–15. 2000. View Article : Google Scholar : PubMed/NCBI | |
Selvey S, Haupt LM, Thompson EW, Matthaei KI, Irving MG and Griffiths LR: Stimulation of MMP-11 (stromelysin-3) expression in mouse fibroblasts by cytokines, collagen and co-culture with human breast cancer cell lines. BMC Cancer. 4:402004. View Article : Google Scholar : PubMed/NCBI | |
Itoh H, Kishore AH, Lindqvist A, Rogers DE and Word RA: Transforming growth factor β1 (TGFβ1) and progesterone regulate matrix metalloproteinases (MMP) in human endometrial stromal cells. J Clin Endocrinol Metab. 97:E888–E897. 2012. View Article : Google Scholar : PubMed/NCBI | |
Buache E, Thai R, Wendling C, Alpy F, Page A, Chenard MP, Dive V, Ruff M, Dejaegere A, Tomasetto C, et al: Functional relationship between matrix metalloproteinase-11 and matrix metalloproteinase-14. Cancer Med. 3:1197–1210. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wu D, Li M, Wang L, Zhou Y, Zhou J, Pan H and Qu P: microRNA-145 inhibits cell proliferation, migration and invasion by targeting matrix metallopeptidase-11 in renal cell carcinoma. Mol Med Rep. 10:393–398. 2014.PubMed/NCBI | |
Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S and Xie K: A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 21:755–764. 2004. View Article : Google Scholar | |
Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, Hinoda Y, Lee CT, Nadaf S, Carbone DP, et al: Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut. 54:591–600. 2005. View Article : Google Scholar | |
Sharma R, Chattopadhyay TK, Mathur M and Ralhan R: Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology. 67:300–309. 2004. View Article : Google Scholar : PubMed/NCBI | |
Mañes S, Mira E, Barbacid MM, Ciprés A, Fernández-Resa P, Buesa JM, Mérida I, Aracil M, Márquez G and Martínez-A C: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem. 272:25706–25712. 1997. View Article : Google Scholar : PubMed/NCBI | |
Liang Q, Xiong H, Gao G, Xiong K, Wang X, Zhao Z, Zhang H and Li Y: Inhibition of basigin expression in glioblastoma cell line via antisense RNA reduces tumor cell invasion and angiogenesis. Cancer Biol Ther. 4:759–762. 2005. View Article : Google Scholar : PubMed/NCBI | |
Tang Y, Nakada MT, Rafferty P, Laraio J, McCabe FL, Millar H, Cunningham M, Snyder LA, Bugelski P and Yan L: Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res. 4:371–377. 2006. View Article : Google Scholar : PubMed/NCBI | |
Tian X, Ye C, Yang Y, Guan X, Dong B, Zhao M and Hao C: Expression of CD147 and matrix metalloproteinase-11 in colorectal cancer and their relationship to clinicopathological features. J Transl Med. 13:3372015. View Article : Google Scholar : PubMed/NCBI | |
Jia L, Cao J, Wei W, Wang S, Zuo Y and Zhang J: CD147 depletion down-regulates matrix metalloproteinase-11, vascular endothelial growth factor-A expression and the lymphatic metastasis potential of murine hepatocarcinoma Hca-F cells. Int J Biochem Cell Biol. 39:2135–2142. 2007. View Article : Google Scholar : PubMed/NCBI | |
Jia L, Zhou H, Wang S, Cao J, Wei W and Zhang J: Deglycosylation of CD147 down-regulates matrix metalloproteinase-11 expression and the adhesive capability of murine hepatocarcinoma cell HcaF in vitro. IUBMB Life. 58:209–216. 2006. View Article : Google Scholar : PubMed/NCBI | |
Honkavuori M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T and Santala M: MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gynecol Oncol. 104:217–221. 2007. View Article : Google Scholar | |
Ogawa M, Ikeuchi K, Watanabe M, Etoh K, Kobayashi T, Takao Y, Anazawa S and Yamazaki Y: Expression of matrix metalloproteinase 7, laminin and type IV collagen-associated liver metastasis in human colorectal cancer: Immunohistochemical approach. Hepatogastroenterology. 52:875–880. 2005.PubMed/NCBI | |
Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, Tsuneyama K and Takano Y: Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 26:3579–3583. 2006.PubMed/NCBI | |
Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH and Lin JT: Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res. 13:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI | |
Mylona E, Nomikos A, Magkou C, Kamberou M, Papassideri I, Keramopoulos A and Nakopoulou L: The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology. 50:338–347. 2007. View Article : Google Scholar : PubMed/NCBI | |
Yang YH, Deng H, Li WM, Zhang QY, Hu XT, Xiao B, Zhu HH, Geng PL and Lu YY: Identification of matrix metalloproteinase 11 as a predictive tumor marker in serum based on gene expression profiling. Clin Cancer Res. 14:74–81. 2008. View Article : Google Scholar : PubMed/NCBI | |
Cheng CW, Yu JC, Wang HW, Huang CS, Shieh JC, Fu YP, Chang CW, Wu PE and Shen CY: The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin Chim Acta. 411:234–241. 2010. View Article : Google Scholar | |
Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP and Boyd MT: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res. 10:2832–2845. 2004. View Article : Google Scholar : PubMed/NCBI | |
Thewes M, Pohlmann G, Atkinson M, Mueller J, Pütz B and Höfler H: Stromelysin-3 (ST-3) mRNA expression in colorectal carcinomas. Localization and clinicopathologic correlations. Diagn Mol Pathol. 5:284–290. 1996. View Article : Google Scholar : PubMed/NCBI | |
Ito Y, Yoshida H, Kakudo K, Nakamura Y, Kuma K and Miyauchi A: Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma. Pathology. 38:421–425. 2006. View Article : Google Scholar : PubMed/NCBI | |
Mellick AS, Blackmore D, Weinstein SR and Griffiths LR: An assessment of MMP and TIMP gene expression in cell lines and stroma - tumour differences in microdissected breast cancer biopsies. Tumour Biol. 24:258–270. 2003. View Article : Google Scholar | |
Têtu B, Trudel D and Wang CS: Proteases by reactive stromal cells in cancer: An attractive therapeutic target. Bull Cancer. 93:944–948. 2006.In French. | |
Hsin CH, Chen MK, Tang CH, Lin HP, Chou MY, Lin CW and Yang SF: High level of plasma matrix metalloproteinase-11 is associated with clinicopathological characteristics in patients with oral squamous cell carcinoma. PLoS One. 9:e1131292014. View Article : Google Scholar : PubMed/NCBI | |
Chang WJ, Du Y, Zhao X, Ma LY and Cao GW: Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol. 20:4586–4596. 2014. View Article : Google Scholar : PubMed/NCBI | |
Pedersen G, Saermark T, Kirkegaard T and Brynskov J: Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol. 155:257–265. 2009. View Article : Google Scholar : PubMed/NCBI | |
Xu CJ and Xu F: MMP-11 and VEGF-C expression correlate with clinical features of colorectal adenocarcinoma. Int J Clin Exp Med. 7:2883–2888. 2014.PubMed/NCBI | |
Eiró N, Fernandez-Garcia B, Vázquez J, Del Casar JM, González LO and Vizoso FJ: A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer. Oncoimmunology. 4:e9922222015. View Article : Google Scholar : PubMed/NCBI | |
Mari BP, Anderson IC, Mari SE, Ning Y, Lutz Y, Kobzik L and Shipp MA: Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J Biol Chem. 273:618–626. 1998. View Article : Google Scholar : PubMed/NCBI | |
Peruzzi D, Mori F, Conforti A, Lazzaro D, De Rinaldis E, Ciliberto G, La Monica N and Aurisicchio L: MMP11: a novel target antigen for cancer immunotherapy. Clin Cancer Res. 15:4104–4113. 2009. View Article : Google Scholar : PubMed/NCBI | |
Hofmeister V, Schrama D and Becker JC: Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother. 57:1–17. 2008. View Article : Google Scholar | |
Yi T, Wei YQ, Tian L, Zhao X, Li J, Deng HX, Wen YJ, Zou CH, Tan GH, Kan B, et al: Humoral and cellular immunity induced by tumor cell vaccine based on the chicken xenogeneic homologous matrix metalloproteinase-2. Cancer Gene Ther. 14:158–164. 2007. View Article : Google Scholar | |
Yokoyama Y, Grünebach F, Schmidt SM, Lazzaro D, De Rinaldis E, Ciliberto G, La Monica N and Aurisicchio L: Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res. 14:5503–5511. 2008. View Article : Google Scholar : PubMed/NCBI | |
Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK and Levin VA: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 20:1383–1388. 2002. View Article : Google Scholar : PubMed/NCBI |